Aeterna Zentaris and Ceapro Announce Merger of Equals to Create a Diversified Biopharmaceutical Company December 14, 2023
Ceapro Inc. Announces Dosing of First Patients in Phase 1-2a Study Assessing Flagship Product Avenanthramides for Potential Applications in Inflammation Based Diseases December 13, 2023
Ceapro Inc. Reports 2023 Third Quarter and Nine-Month Financial Results and Operational Highlights November 29, 2023
Ceapro Inc. Initiates Phase 1-2a Study Assessing Its Flagship Product Avenanthramides for Potential Applications in Inflammation Based Diseases November 27, 2023
Ceapro Inc. Enters into Technical Collaboration with NATEX Prozesstechnologie GmbH and Provides Update on the Scale-Up Project for its Patented Pressurized Gas eXpanded (PGX) Technology November 7, 2023
Ceapro Inc. Reports 2023 Second Quarter and Six-Month Financial Results and Provides Corporate Update August 29, 2023
Ceapro Extends Exclusive International Supply and Distribution Agreement with Leading Global Provider of Active Ingredients, Symrise August 25, 2023